Published in Biochem J on October 01, 2004
Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A (2005) 2.21
Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute? Am J Physiol Heart Circ Physiol (2015) 2.16
Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney Int (2012) 1.67
ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good. Am J Physiol Regul Integr Comp Physiol (2010) 1.51
Sex differences in angiotensin-converting enzyme modulation of Ang (1-7) levels in normotensive WKY rats. Am J Hypertens (2013) 1.41
The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function. Am J Physiol Renal Physiol (2010) 1.34
A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol Rev (2012) 1.31
The renin-angiotensin system and diabetes: an update. Vasc Health Risk Manag (2008) 1.30
Injections of angiotensin-converting enzyme 2 inhibitor MLN4760 into nucleus tractus solitarii reduce baroreceptor reflex sensitivity for heart rate control in rats. Exp Physiol (2008) 1.24
Update on the Angiotensin converting enzyme 2-Angiotensin (1-7)-MAS receptor axis: fetal programing, sex differences, and intracellular pathways. Front Endocrinol (Lausanne) (2014) 1.22
Species-specific inhibitor sensitivity of angiotensin-converting enzyme 2 (ACE2) and its implication for ACE2 activity assays. Am J Physiol Regul Integr Comp Physiol (2011) 1.18
The importance of the intrarenal renin-angiotensin system. Nat Clin Pract Nephrol (2008) 1.15
Identification of intracellular proteins and signaling pathways in human endothelial cells regulated by angiotensin-(1-7). J Proteomics (2015) 1.09
Chronic AT2 receptor activation increases renal ACE2 activity, attenuates AT1 receptor function and blood pressure in obese Zucker rats. Kidney Int (2013) 1.07
Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail (2009) 1.04
Nonclassical renin-angiotensin system and renal function. Compr Physiol (2012) 1.02
Differential regulation of circulating and renal ACE2 and ACE in hypertensive mRen2.Lewis rats with early-onset diabetes. Am J Physiol Renal Physiol (2012) 1.01
New angiotensins. J Mol Med (Berl) (2008) 1.00
Regulation of urinary ACE2 in diabetic mice. Am J Physiol Renal Physiol (2013) 0.99
Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice. Am J Physiol Renal Physiol (2011) 0.97
Network modeling reveals steps in angiotensin peptide processing. Hypertension (2013) 0.95
Renin-angiotensin system in the pathogenesis of liver fibrosis. World J Gastroenterol (2009) 0.94
An evolving story of angiotensin-II-forming pathways in rodents and humans. Clin Sci (Lond) (2014) 0.93
Therapeutic modalities in diabetic nephropathy: standard and emerging approaches. J Gen Intern Med (2011) 0.92
ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury. Curr Hypertens Rep (2014) 0.92
Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides. Sci Rep (2012) 0.91
Angiotensin-converting enzyme 2: the first decade. Int J Hypertens (2011) 0.90
Chymase mediates angiotensin-(1-12) metabolism in normal human hearts. J Am Soc Hypertens (2013) 0.90
Divergent pathways for the angiotensin-(1-12) metabolism in the rat circulation and kidney. Peptides (2012) 0.90
Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition. Clin Sci (Lond) (2010) 0.89
The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease. Pediatr Nephrol (2011) 0.89
Overexpression of catalase prevents hypertension and tubulointerstitial fibrosis and normalization of renal angiotensin-converting enzyme-2 expression in Akita mice. Am J Physiol Renal Physiol (2013) 0.87
Recombinant Expression and Characterization of Human and Murine ACE2: Species-Specific Activation of the Alternative Renin-Angiotensin-System. Int J Hypertens (2012) 0.86
Angiotensin II relaxations of bovine adrenal cortical arteries: role of angiotensin II metabolites and endothelial nitric oxide. Hypertension (2008) 0.84
The N domain of somatic angiotensin-converting enzyme negatively regulates ectodomain shedding and catalytic activity. Biochem J (2005) 0.84
Identification and characterisation of the angiotensin converting enzyme-3 (ACE3) gene: a novel mammalian homologue of ACE. BMC Genomics (2007) 0.84
Differential mechanisms of ang (1-7)-mediated vasodepressor effect in adult and aged candesartan-treated rats. Int J Hypertens (2011) 0.84
High glucose activates the alternative ACE2/Ang-(1-7)/Mas and APN/Ang IV/IRAP RAS axes in pancreatic β-cells. Int J Mol Med (2013) 0.84
Engineering neprilysin activity and specificity to create a novel therapeutic for Alzheimer's disease. PLoS One (2014) 0.83
Angiotensin converting enzyme 2, Angiotensin-(1-7), and receptor MAS axis in the kidney. Int J Hypertens (2012) 0.83
Hydrolysis of angiotensin peptides by human angiotensin I-converting enzyme and the resensitization of B2 kinin receptors. Hypertension (2005) 0.83
Angiotensin-(1-12): a chymase-mediated cellular angiotensin II substrate. Curr Hypertens Rep (2014) 0.83
High glucose-induced Nox1-derived superoxides downregulate PKC-betaII, which subsequently decreases ACE2 expression and ANG(1-7) formation in rat VSMCs. Am J Physiol Heart Circ Physiol (2008) 0.83
Targeted catalytic inactivation of angiotensin converting enzyme by lisinopril-coupled transition-metal chelates. J Am Chem Soc (2012) 0.83
Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells. J Virol (2014) 0.83
In vivo expression of angiotensin-(1-7) lowers blood pressure and improves baroreflex function in transgenic (mRen2)27 rats. J Cardiovasc Pharmacol (2012) 0.82
Toxicological and toxicokinetic analysis of angiotensin (1-7) in two species. J Pharm Sci (2011) 0.82
Angiotensin-(1-7)-mediated signaling in cardiomyocytes. Int J Hypertens (2012) 0.81
Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. Int J Pept (2012) 0.81
Kinetic probes for inter-domain co-operation in human somatic angiotensin-converting enzyme. Biochem J (2005) 0.81
Plasma and Kidney Angiotensin Peptides: Importance of the Aminopeptidase A/Angiotensin III Axis. Am J Hypertens (2015) 0.81
Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2. Am J Physiol Gastrointest Liver Physiol (2009) 0.80
Angiotensin-Converting Enzyme 2 Deficiency Aggravates Glucose Intolerance via Impairment of Islet Microvascular Density in Mice with High-Fat Diet. J Diabetes Res (2013) 0.80
The role of angiotensin-(1-7) receptor Mas in spermatogenesis in mice and rats. J Anat (2009) 0.80
Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment. Diabetes Metab Syndr Obes (2010) 0.80
Protective Role of the ACE2/Ang-(1-9) Axis in Cardiovascular Remodeling. Int J Hypertens (2012) 0.78
Chronic nerve injury-induced Mas receptor expression in dorsal root ganglion neurons alleviates neuropathic pain. Exp Ther Med (2015) 0.78
Increasing serum soluble angiotensin-converting enzyme 2 activity after intensive medical therapy is associated with better prognosis in acute decompensated heart failure. J Card Fail (2013) 0.78
Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease. J Diabetes Res (2016) 0.78
Gender Difference in Renal Blood Flow Response to Angiotensin II Administration after Ischemia/Reperfusion in Rats: The Role of AT2 Receptor. Adv Pharmacol Sci (2016) 0.77
Temporal Gene Expression Analysis and RNA Silencing of Single and Multiple Members of Gene Family in the Lone Star Tick Amblyomma americanum. PLoS One (2016) 0.77
Angiotensin peptides and nitric oxide in cardiovascular disease. Antioxid Redox Signal (2012) 0.77
MAS-mediated antioxidant effects restore the functionality of angiotensin converting enzyme 2-angiotensin-(1-7)-MAS axis in diabetic rat carotid. Biomed Res Int (2014) 0.77
Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure. Circ Res (2016) 0.77
Structural libraries of protein models for multiple species to understand evolution of the renin-angiotensin system. Gen Comp Endocrinol (2014) 0.76
Biosynthetic pathways and the role of the MAS receptor in the effects of Angiotensin-(1-7) in smooth muscles. Int J Hypertens (2011) 0.76
Differential effect of low dose thiazides on the Renin Angiotensin system in genetically hypertensive and normotensive rats. J Am Soc Hypertens (2010) 0.76
Neprilysin is Required for Angiotensin-(1-7)'s Ability to Enhance Insulin secretion via its Proteolytic Activity to Generate Angiotensin-(1-2). Diabetes (2017) 0.76
Pharmacological characterization of a novel non-AT1, non-AT2 angiotensin binding site identified as neurolysin. Endocrine (2013) 0.75
Angiotensin converting enzyme versus angiotensin converting enzyme-2 selectivity of MLN-4760 and DX600 in human and murine bone marrow-derived cells. Eur J Pharmacol (2016) 0.75
Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy. Eur J Heart Fail (2016) 0.75
Functional Local Renin-Angiotensin System in Human and Rat Periodontal Tissue. PLoS One (2015) 0.75
Structural basis of Ac-SDKP hydrolysis by Angiotensin-I converting enzyme. Sci Rep (2015) 0.75
Kinetic and structural characterization of amyloid-β peptide hydrolysis by human angiotensin-1-converting enzyme. FEBS J (2016) 0.75
Many Faces of Renin-angiotensin System - Focus on Eye. Open Ophthalmol J (2017) 0.75
ACE phenotyping in human heart. PLoS One (2017) 0.75
Renin Angiotensin Aldosterone Inhibition in the Treatment of Cardiovascular Disease. Pharmacol Res (2017) 0.75
Is the renin-angiotensin system actually hypertensive? Pediatr Nephrol (2013) 0.75
Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients. PLoS One (2017) 0.75
Measurement of protein using bicinchoninic acid. Anal Biochem (1985) 74.03
A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res (2000) 6.78
Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature (2002) 5.02
A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem (2000) 4.21
The kinetics of reversible tight-binding inhibition. Methods Enzymol (1979) 4.13
Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem (2002) 3.81
Structure of the angiotensin I-converting enzyme gene. Two alternate promoters correspond to evolutionary steps of a duplicated gene. J Biol Chem (1991) 3.22
Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci U S A (1988) 3.21
Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J (1989) 2.24
The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bioessays (2001) 2.23
Counterregulatory actions of angiotensin-(1-7). Hypertension (1997) 1.87
The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J Biol Chem (1991) 1.86
Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: insights from selective inhibitors. Circ Res (2003) 1.69
Expression and characterization of recombinant human angiotensin I-converting enzyme. Evidence for a C-terminal transmembrane anchor and for a proteolytic processing of the secreted recombinant and plasma enzymes. J Biol Chem (1991) 1.65
Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2. Circulation (2003) 1.52
The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci (2002) 1.51
Human kidney "enkephalinase", a neutral metalloendopeptidase that cleaves active peptides. Biochemistry (1983) 1.37
Pig kidney angiotensin converting enzyme. Purification and characterization of amphipathic and hydrophilic forms of the enzyme establishes C-terminal anchorage to the plasma membrane. Biochem J (1987) 1.32
Purification of angiotensin-converting enzyme from rabbit lung and human plasma by affinity chromatography. J Biol Chem (1985) 1.22
The role of ACE2 in cardiovascular physiology. Trends Cardiovasc Med (2003) 1.21
N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE. Hypertension (1998) 1.21
A zinc metalloendopeptidase associated with dog pancreatic membranes. J Biol Chem (1980) 1.11
Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate. Circulation (2003) 1.08
Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence. Biochemistry (2003) 1.04
Inhibition by converting enzyme inhibitors of pig kidney aminopeptidase P. Hypertension (1992) 1.04
An alternative strategy for the radioimmunoassay of angiotensin peptides using amino-terminal-directed antisera: measurement of eight angiotensin peptides in human plasma. J Hypertens (1990) 1.04
Shedding of somatic angiotensin-converting enzyme (ACE) is inefficient compared with testis ACE despite cleavage at identical stalk sites. Biochem J (2000) 1.02
Molecular biology of the angiotensin I converting enzyme: I. Biochemistry and structure of the gene. J Hypertens (1993) 1.01
Angiotensin 1-9 and 1-7 release in human heart: role of cathepsin A. Hypertension (2002) 1.00
Vasopeptidase inhibition: a double-edged sword? Hypertension (2003) 0.99
RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites. Proc Natl Acad Sci U S A (1999) 0.98
Cell biology and genetics of angiotensin in cardiovascular disease. J Hypertens Suppl (1994) 0.96
Evidence for the negative cooperativity of the two active sites within bovine somatic angiotensin-converting enzyme. FEBS Lett (2003) 0.95
Hypothesis: ACE2 modulates blood pressure in the mammalian organism. Hypertension (2003) 0.94
Selective inhibition of the C-domain of angiotensin I converting enzyme by bradykinin potentiating peptides. Biochemistry (2002) 0.92
Arg(1098) is critical for the chloride dependence of human angiotensin I-converting enzyme C-domain catalytic activity. J Biol Chem (2001) 0.91
Inhibition of rabbit lung angiotensin-converting enzyme by N alpha-[(S)-1-carboxy-3-phenylpropyl]L-alanyl-L-proline and N alpha-[(S)-1-carboxy-3-phenylpropyl]L-lysyl-L-proline. J Biol Chem (1985) 0.91
Cell-specific activity of neprilysin 2 isoforms and enzymic specificity compared with neprilysin. Biochem J (2002) 0.91
Effects of the N-terminal sequence of ACE on the properties of its C-domain. Hypertension (2000) 0.87
Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin. J Mol Cell Cardiol (2002) 0.85
Heart failure: recent advances in prevention and treatment. Rev Cardiovasc Med (2000) 0.84
Isolation of acein-2, a novel angiotensin-I-converting enzyme inhibitory peptide derived from a tryptic hydrolysate of human plasma. FEBS Lett (2000) 0.84
Angiotensin converting enzyme and angiotensin II type 1-receptor gene polymorphisms and risk of ischaemic heart disease. Cardiovasc Res (1999) 0.83
Essential hypertension : part II: treatment. Circulation (2000) 0.82
A pair of ACEs, for openers? Circ Res (2000) 0.79
Two ACEs and a heart. Nature (2002) 0.79
The Renin-Angiotensin and fibrinolytic systems co-conspirators in the pathogenesis of ischemic cardiovascular disease. Trends Cardiovasc Med (1996) 0.78
The angiotensin type 1 and type 2 receptor families. Siblings or cousins? Adv Exp Med Biol (1995) 0.78
Characteristics of angiotensin converting enzyme and its role in the metabolism of angiotensin I by endothelium. J Cardiovasc Pharmacol (1986) 0.78
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Shedding light on ADAM metalloproteinases. Trends Biochem Sci (2005) 2.41
ADAMs family members as amyloid precursor protein alpha-secretases. J Neurosci Res (2003) 2.29
Activation markers of coagulation and fibrinolysis in twins: heritability of the prethrombotic state. Lancet (2002) 2.26
Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc Natl Acad Sci U S A (2007) 2.05
Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci U S A (2003) 2.03
Identification, classification, and expression of RAGE gene splice variants. FASEB J (2007) 1.96
Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem (2005) 1.73
Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood (2002) 1.72
Interactions between factor XIII and the alphaC region of fibrinogen. Blood (2011) 1.58
The prion protein and lipid rafts. Mol Membr Biol (2006) 1.54
Increased fibrinogen levels among South Asians versus Whites in the United Kingdom are not explained by common polymorphisms. Am J Epidemiol (2002) 1.52
The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci (2002) 1.51
Genome-wide association study for circulating tissue plasminogen activator levels and functional follow-up implicates endothelial STXBP5 and STX2. Arterioscler Thromb Vasc Biol (2014) 1.45
Altered fibrin clot structure and function in the healthy first-degree relatives of subjects with intermittent claudication. J Vasc Surg (2008) 1.43
The activation peptide cleft exposed by thrombin cleavage of FXIII-A(2) contains a recognition site for the fibrinogen α chain. Blood (2013) 1.42
Elevated C-reactive protein and long-term mortality after ischaemic stroke: relationship with markers of endothelial cell and platelet activation. Stroke (2009) 1.41
Assigning functions to distinct regions of the N-terminus of the prion protein that are involved in its copper-stimulated, clathrin-dependent endocytosis. J Cell Sci (2005) 1.38
Ligand-stimulated VEGFR2 signaling is regulated by co-ordinated trafficking and proteolysis. Traffic (2010) 1.36
Dual mechanisms for shedding of the cellular prion protein. J Biol Chem (2004) 1.32
Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease? J Neurochem (2011) 1.32
Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res (2008) 1.30
Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? J Neurochem (2002) 1.30
Ischemic stroke is associated with the ABO locus: the EuroCLOT study. Ann Neurol (2013) 1.30
Angiotensin-converting enzyme as a GPIase: a critical reevaluation. Nat Med (2005) 1.28
Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rep (2008) 1.27
The involvement of lipid rafts in Alzheimer's disease. Mol Membr Biol (2006) 1.26
Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation. Blood (2012) 1.26
Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease. Trends Mol Med (2005) 1.26
Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension (2006) 1.25
Functional analysis of fibrin {gamma}-chain cross-linking by activated factor XIII: determination of a cross-linking pattern that maximizes clot stiffness. Blood (2007) 1.25
The low-density lipoprotein receptor-related protein 1 (LRP1) mediates the endocytosis of the cellular prion protein. Biochem J (2007) 1.25
Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J (2009) 1.24
The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a {beta}-secretase-dependent pathway. J Biol Chem (2010) 1.21
Role of ADAMs in the ectodomain shedding and conformational conversion of the prion protein. J Biol Chem (2009) 1.19
The role of ADAM10 and ADAM17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein. Eur J Biochem (2004) 1.18
Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation (2003) 1.17
Lipid Rafts: Linking Alzheimer's Amyloid-β Production, Aggregation, and Toxicity at Neuronal Membranes. Int J Alzheimers Dis (2010) 1.17
Genetic and environmental determinants of fibrin structure and function: relevance to clinical disease. Arterioscler Thromb Vasc Biol (2004) 1.17
Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation (2002) 1.13
Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003. Eur Heart J (2007) 1.12
Reactive oxygen species-mediated beta-cleavage of the prion protein in the cellular response to oxidative stress. J Biol Chem (2005) 1.12
Predictive variables for mortality after acute ischemic stroke. Stroke (2007) 1.11
Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. J Biol Chem (2005) 1.10
ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary. Diab Vasc Dis Res (2014) 1.10
Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet (2003) 1.10
Visualization of detergent solubilization of membranes: implications for the isolation of rafts. Biophys J (2007) 1.09
alpha-cleavage of the prion protein occurs in a late compartment of the secretory pathway and is independent of lipid rafts. Mol Cell Neurosci (2008) 1.08
Sodium valproate: an old drug with new roles. Trends Pharmacol Sci (2009) 1.07
The amyloid precursor protein: a biochemical enigma in brain development, function and disease. FEBS Lett (2013) 1.07
Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis (2009) 1.07
Prion protein facilitates uptake of zinc into neuronal cells. Nat Commun (2012) 1.07
Prion protein and Alzheimer disease. Prion (2009) 1.05
Genetic predictors of fibrin D-dimer levels in healthy adults. Circulation (2011) 1.05
The N-terminal region of the prion protein ectodomain contains a lipid raft targeting determinant. J Biol Chem (2003) 1.04
Glypican-1 mediates both prion protein lipid raft association and disease isoform formation. PLoS Pathog (2009) 1.04
Cell biology, regulation and inhibition of beta-secretase (BACE-1). FEBS J (2009) 1.04
Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence. Biochemistry (2003) 1.04
The prion protein and neuronal zinc homeostasis. Trends Biochem Sci (2003) 1.04
Increased circulating insulin-like growth factor-1 in late-onset Alzheimer's disease. J Alzheimers Dis (2007) 1.04
Symmetrical dimethylarginine predicts mortality in the general population: observations from the Dallas heart study. Arterioscler Thromb Vasc Biol (2013) 1.03
PCSK9: an emerging target for treatment of hypercholesterolemia. Expert Opin Ther Targets (2011) 1.02
Inflammation and thrombosis in diabetes. Thromb Haemost (2011) 1.02
Prion protein-mediated toxicity of amyloid-β oligomers requires lipid rafts and the transmembrane LRP1. J Biol Chem (2013) 1.01
Increasing circulating IGFBP1 levels improves insulin sensitivity, promotes nitric oxide production, lowers blood pressure, and protects against atherosclerosis. Diabetes (2012) 1.01
Effects of hypoxia and oxidative stress on expression of neprilysin in human neuroblastoma cells and rat cortical neurones and astrocytes. Neurochem Res (2007) 1.00
The molecular physiology and pathology of fibrin structure/function. Blood Rev (2005) 1.00
Prion protein interacts with BACE1 protein and differentially regulates its activity toward wild type and Swedish mutant amyloid precursor protein. J Biol Chem (2011) 1.00
The insulin-like growth factor-1 receptor is a negative regulator of nitric oxide bioavailability and insulin sensitivity in the endothelium. Diabetes (2011) 1.00
A broad-spectrum fluorescence-based peptide library for the rapid identification of protease substrates. Proteomics (2006) 1.00
Common variation in the C-terminal region of the fibrinogen beta-chain: effects on fibrin structure, fibrinolysis and clot rigidity. Blood (2007) 0.99
Endothelial cell confluence regulates Weibel-Palade body formation. Mol Membr Biol (2005) 0.99
Nuclear signalling by membrane protein intracellular domains: the AICD enigma. Cell Signal (2011) 0.98
An endocrinologist's guide to the clock. J Clin Endocrinol Metab (2011) 0.98
The kinetics of phase separation in asymmetric membranes. Biophys J (2005) 0.97
Lipid rafts and Alzheimer's disease: protein-lipid interactions and perturbation of signaling. Front Physiol (2012) 0.97
Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system. Biochem Pharmacol (2007) 0.97
Surface coat remodeling during differentiation of Trypanosoma brucei. J Biol Chem (2003) 0.97
Novel role of the IGF-1 receptor in endothelial function and repair: studies in endothelium-targeted IGF-1 receptor transgenic mice. Diabetes (2012) 0.97
The role of lipid rafts in prion protein biology. Front Biosci (Landmark Ed) (2011) 0.96